Cite
The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
MLA
Clayton, Anita H., et al. “The Magnitude and Sustainability of Treatment Benefit of Zuranolone on Function and Well-Being as Assessed by the SF-36 in Adult Patients with MDD and PPD: An Integrated Analysis of 4 Randomized Clinical Trials.” Journal of Affective Disorders, vol. 351, Apr. 2024, pp. 904–14. EBSCOhost, https://doi.org/10.1016/j.jad.2024.01.268.
APA
Clayton, A. H., Suthoff, E., Jain, R., Kosinski, M., Fridman, M., Deligiannidis, K. M., Meltzer-Brody, S., Chen, S.-Y., Gervitz, L., Huang, M.-Y., Trivedi, M., & Bonthapally, V. (2024). The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials. Journal of Affective Disorders, 351, 904–914. https://doi.org/10.1016/j.jad.2024.01.268
Chicago
Clayton, Anita H., Ellison Suthoff, Rakesh Jain, Mark Kosinski, Moshe Fridman, Kristina M. Deligiannidis, Samantha Meltzer-Brody, et al. 2024. “The Magnitude and Sustainability of Treatment Benefit of Zuranolone on Function and Well-Being as Assessed by the SF-36 in Adult Patients with MDD and PPD: An Integrated Analysis of 4 Randomized Clinical Trials.” Journal of Affective Disorders 351 (April): 904–14. doi:10.1016/j.jad.2024.01.268.